UBS lowered the firm’s price target on Harmony Biosciences (HRMY) to $48 from $55 and keeps a Buy rating on the shares. Harmony reported Q1 in-line with consensus estimates, but notes a competitor’s Q2 update on Fragile X Syndrome, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target lowered to $32 from $33 at BofA
- Positive Outlook for Harmony Biosciences’ ZYN002: Strong Phase 2 Data and Global Rights Support Buy Rating
- Positive Outlook for Harmony Biosciences Holdings Based on Promising ZYN-002 Study Results
- Harmony Biosciences Appoints Ron Philip to Board
- Harmony Biosciences Appoints New Chief Commercial Officer